Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC boosted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 549.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 159,477 shares of the medical equipment provider's stock after buying an additional 134,931 shares during the quarter. Janus Henderson Group PLC owned 0.08% of Zimmer Biomet worth $17,216,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ZBH. Ashton Thomas Securities LLC purchased a new position in Zimmer Biomet in the third quarter valued at $28,000. Bangor Savings Bank purchased a new position in shares of Zimmer Biomet in the 3rd quarter valued at about $31,000. Family Firm Inc. acquired a new position in shares of Zimmer Biomet during the second quarter worth about $33,000. Brooklyn Investment Group purchased a new stake in shares of Zimmer Biomet during the third quarter worth approximately $35,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in Zimmer Biomet in the second quarter valued at approximately $43,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH traded down $1.13 on Friday, reaching $108.03. The company's stock had a trading volume of 1,141,079 shares, compared to its average volume of 1,403,075. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. Zimmer Biomet Holdings, Inc. has a 52-week low of $101.47 and a 52-week high of $133.90. The stock's 50-day moving average is $107.52 and its two-hundred day moving average is $108.95. The stock has a market capitalization of $21.51 billion, a P/E ratio of 20.54, a PEG ratio of 1.99 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts' consensus estimates of $1.74. The company had revenue of $1.82 billion during the quarter, compared to analysts' expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm's revenue for the quarter was up 4.1% on a year-over-year basis. During the same period last year, the firm earned $1.65 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on ZBH. Wolfe Research began coverage on shares of Zimmer Biomet in a report on Tuesday, September 10th. They set a "peer perform" rating for the company. Oppenheimer lowered their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating for the company in a research note on Tuesday, October 15th. Royal Bank of Canada raised their price target on Zimmer Biomet from $120.00 to $125.00 and gave the company an "outperform" rating in a research note on Monday, November 4th. BTIG Research lowered their price objective on Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating for the company in a research report on Thursday, October 3rd. Finally, Canaccord Genuity Group cut their target price on Zimmer Biomet from $120.00 to $115.00 and set a "hold" rating on the stock in a research report on Tuesday, September 10th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Zimmer Biomet has an average rating of "Hold" and a consensus price target of $123.22.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.